Last updated October 21, 2026. Approval line checked October 21, 2026. Compounding sources checked October 10, 2026.
FDA status
Not approved
Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.
FDA primary source on fileBy signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Human Observational. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 3/5. 420 PubMed citations indexed.
Products sold as "research use only" are not approved for human use. FDA warning.
First-generation GHRP ghrelin analog stimulating GH release and increasing appetite via hypothalamic NPY activation; also shows cytoprotective effects in cardiac tissue.
What the literature studies
GH Release & Appetite Stimulation
Evidence tier
Human Observational
Compounding record
503B Category 2 / 503A Category 3
503B Category 2 / 503A Category 3. FDA substance context: GHRP-6. 503B Category 2 identifies potential significant safety risks; 503A Category 3 means the nomination lacks adequate supporting information. Neither classification establishes approval or compounding eligibility. Other routes are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source checked October 10, 2026. This compounding label is separate from the approval line above.
cortisol and blood glucose elevation; significant appetite stimulation may be undesirable.
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.